Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06767605

Spanish Registry of Autoimmune and Cholestatic Liver Diseases (ColHai)

The purpose of the registry is to know the status of primary biliary colgantis, autoimmune hepatitis, primary sclerosing cholagitis and genetic cholestatic diseases in Spain.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Hepatitis Autoimmune Disease Abnormalities, Multiple Alagille Syndrome Bile Duct Diseases Biliary Tract Diseases Cardiovascular Abnormalities Cardiovascular Diseases Cholangitis Cholangitis, Sclerosing Cholestasis Cholestasis, Intrahepatic Cholestatic Genetic Diseases Chronic Disease Congenital Abnormalities Congenital, Hereditary, and Neonatal Diseases and Abnormalities Digestive System Diseases Disease Attributes Fibrosis Genetic Diseases, Inborn Heart Defects, Congenital Hyperbilirubinemia, Hereditary Hyperbilirubinemia, Neonatal Infant, Newborn, Diseases Jaundice, Chronic Idiopathic Jaundice, Neonatal Liver Cirrhosis Liver Cirrhosis, Biliary Liver Diseases Metabolic Diseases Metabolism, Inborn Errors Nutritional and Metabolic Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Primary Biliary Cholangitis (PBC) Primary Sclerosing Cholangitis (PSC)

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Hospital Clinic

Barcelona, Spain

Location status: Recruiting

Location contact

Maria Carlota Londoño Londoño

CONTACT

[email protected]

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with a confirmed diagnosis for PBC, HAI, PSC, genetic cholestatic disease

Exclusion criteria

  • Refusal to sign the informed consent for the study

Treatment and study plan

Primary outcomes

  1. Prevalence and characteristics of autoimmune and cholestatic liver disease in Spain

    Time frame: 2025

    Evaluation of clinical characteristics of autoimmune and cholestatic liver diseases

Secondary outcomes

  1. Development of liver-related events in autoimmune ahd cholestatic liver diseases

    Time frame: 2025

  2. Treatment of autoimmune and cholestatic liver diseases in Spain

    Time frame: 2016-2030

Study contacts

Contact information is provided by the study sponsor or research team.

Asociación Española para el Estudio del Hígado Asociación Espa

CONTACT

[email protected]

0034915551119

Sponsors and collaborators

Lead sponsor

Asociación Española para el Estudio del Hígado

Other

Registry information

Official study title

Registro Español de Enfermedades Hepáticas Colestásicas y Autoinmunes (ColHai)

Acronym: ColHai

Important dates

Study start
2016
Primary completion
2030
Study completion
2030
First posted
Jan 10, 2025
Registry last updated
Jan 10, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.